From old to new anticoagulants: The role of the pathologist;Des anciens aux nouveaux anticoagulants: Le rôle du biologiste

Annales de Biologie Clinique

Volumn 67, Issue 5, 2009, Pages 525-534

  Samama, Meyer Michel ^a   Depasse, F ^a  

^a Laboratoire Biomnis   (France)

Author keywords

Dabigatran etexilate; Factor IIa inhibitors; Factor Xa inhibitors; Heparins; Rivaroxaban; Vitamin K antagonists (VKA)

Indexed keywords

ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BLOOD CLOTTING FACTOR 10; DABIGATRAN ETEXILATE; FIBRINOLYTIC AGENT; FONDAPARINUX; HIRUDIN DERIVATIVE; LEPIRUDIN; MORPHOLINE DERIVATIVE; POLYSACCHARIDE; PYRIDINE DERIVATIVE; RECOMBINANT PROTEIN; RIVAROXABAN; THIOPHENE DERIVATIVE;

ARTICLE; BLOOD CLOTTING; DRUG ANTAGONISM; HUMAN; PHYSIOLOGY;

ANTICOAGULANTS; BENZIMIDAZOLES; BLOOD COAGULATION; FACTOR X; FIBRINOLYTIC AGENTS; HIRUDINS; HUMANS; MORPHOLINES; POLYSACCHARIDES; PYRIDINES; RECOMBINANT PROTEINS; THIOPHENES;

EID: 73949100783     PISSN: 00033898     EISSN: 19506112     Source Type: Journal    
DOI: 10.1684/abc.2009.0359     Document Type: Article

References (34)

1. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. American college of Chest Physicians. Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2008; 133: 141S-159S. (Pubitemid 351892966)
2. Ansell J, Hirsch J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2008; 133: 160S-198S. (Pubitemid 351892967)
3. th edition). Chest 2008; 133: 340S-380S.
4. Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. Thromb Haemost 2008; 99: 819-29.
5. Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost 2008; 99: 830-9.
6. Savi P, Herault JP, Duchaussoy P, Millet L, Schaeffer P, Petitout M, et al. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy. J Thromb Haemost 2008; 6: 1697-706.
7. Potron G, Sié P. Traitement anticoagulant oral: antivitamines K (AVK). In: Samama MM, et al., eds. Hémorragies et thromboses - Du diagnostic aux traitements. Paris: Masson, 2008: 313-24.
8. Clark NP. Low-molecular weight heparin use in obese, the elderly and in renal insufficiency. Thromb Res 2008; 123: S58-61.
9. Siguret V, Pautas E, Gouin-Thibault I. Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to wafarin. Vitam Horm 2008; 78: 247-64.
10. Francis CW. New issues in oral anticoagulants. Hematology Am Soc Hematol Educ Program 2008: 259-65.
11. Moreau C, Siguret V, Loriot MA. Pharmacogénétique et antivitamine K aujourd'hui: un débat ouvert. Rev Med Int 2009; sous presse.
12. Weitz J, Hirsch J, Samama MM. New antithrombotic drugs: American College et Chest Physicians evidence-based clinical practice guidelines. Chest 2008; 133: 234S-256S. (Pubitemid 351892968)
13. Haas S. New anticoagulants: towards the development of an « ideal » anticoagulant. Vasa 2009; 38: 13-29.
14. Eriksson BI, Quinlan DJ, Weitz JL. Comparative pharmacodynamics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009; 48: 1-22.
15. Turpie AG. The top 4 advances in antithrombotic care in the last year. Thromb Res 2008; 123: S2-6.
16. Crowther MA, Weitz JL. Ximelagatran: the first oral direct thrombin inhibitor. Expert Opin Investig Drugs 2004; 13: 403-13.
17. Kher A, Gouin I, Samama MM. Surveillance du traitement par les inhibiteurs directs de la thrombine: temps de céphaline avec activateur ou temps d'écarine. Ann Biol Clin 2000; 58: 575-9.
18. Samama MM, Le Flem L, Guinet C, Gerotziafas G, Depasse F. Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants. J Thrombo Haemost 2007; 5: 2554-6.
19. Greinacher A. Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy. Expert Rev Cardiovasc Ther 2004; 2: 339-57.
20. Baetz BE, Spinler SA. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 2008; 11: 1354-73.
21. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. In vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007; 98: 155-62. (Pubitemid 47078782)
22. Samama MM, Le Flem L, Guinet C, Depasse F, Perzborn E, Van- Ryn J. Comparative responses of some clotting assays to fondaparinux, dabigatran and rivaroxaban. Pathophysiology of hemostasis and thrombosis. XXth International Congress on Thrombosis - Athens - 25-28 June 2008 Abstract p. 98.
23. Bounameaux H. The novel anticoagulants: entering a new era. Swiss Med Wkly 2009; 139: 60-4.
24. Depasse F, Kher A, Samama MM. Moyens thérapeutiques modernes et d'avenir. In: Samama MM, et al., eds. Hémorragies et thromboses - Du diagnostic aux traitements. Paris: Masson, 2008: 341-5.
25. Walenga JM, Jeske WP, Bara L, Samama MM, Fareed J. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Thromb Res 1997; 86: 1-36.
26. Walenga JM, Jeske WP, Samama MM, Frapaise FX, Bick RL, Fareed J. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin Invest Drugs 2002; 11: 397-407. (Pubitemid 34213393)
27. Turpie AG, Lensing AW, Fuji T, Boyle DA. Pharmacokinetic and clinical data supporting the use of fondaparinux 1, 5 mg once daily in the prevention of venous thromboembolism in renally impaired patients. Blood Coagul Fibrinolysis 2009; 20: 114-21.
28. Depasse F, Gerotziafas GT, Busson J, Van Dreden P, Samama MM. Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra) anti-Xa activity. J Thromb Haemost 2004; 2: 346-8.
29. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY-59 7939, an oral, direct, factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412-21.
30. Gerotziafas GT, Elalamy I, Depasse F, Perzborn E, Samama MM. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost 2007; 5: 886-8.
31. Mega J, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, et al. On behalf of the ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI46): a randomised, double-blind, phase II trial. Lancet 2009; 374: 29-38.
32. Samama MM. Les nouveaux anticoagulants. Focus Cardiology 2009; article soumis.
33. Haas S. Rivaroxaban - an oral direct factor Xa inhibitor: lessons from a broad clinical study programme. Eur J Haematol 2009; 82: 339-49.
34. Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008; 100: 453-61.